Entries by oslocancer

Machine-learning for immunotherapy

A prestigious EU-grant will advance OncoImmunity’s machine-learning approach to develop personalized cancer immunotherapy. The bioinformatics company OncoImmunity AS is empowering cancer immunotherapy with artificial intelligence. They use innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers. What does this really mean? It means that the software they have developed helps to identify […]

Industrial precision against cancer 

Kongsberg Beam Technology wants to direct the precision technology from advanced industrial control systems to hit tumors in the human body.  — We want to use Norwegian spearhead technology to combat cancer, Per Håvard Kleven said from the stage as he pitched the idea of his start-up at the DNB Nordic Healthcare Conference 2018. He is […]

Days to partner up

Roche is looking for new partners in the innovative Norwegian life science scene.  Roche is one of the largest pharmaceutical companies in the world with about 800 ongoing clinical trials. Within cancer research and development, this translates into about 500 clinical trials for many different types of cancer. Roche is a member in Oslo Cancer Cluster.  […]

The e-health meeting place

Starting next year, Oslo Cancer Cluster will co-power the conference E-health in Norway (EHiN). – This is a natural continuation of the work we do in digitalisation, for a better understanding of cancer and better patient treatment, said Ketil Widerberg, General Manager of Oslo Cancer Cluster, at this year’s conference. The Norwegian Ministry of Health and Care […]

Let us cooperate on precise health technologies

International cooperation is key to fulfilling our vision of making cancer treatments more precise, and giving the patients new treatments more quickly. This opinion piece is written by Ketil Widerberg, General Manager at Oslo Cancer Cluster. It was first published in the Norwegian newspaper Today’s Medicine, Dagens Medisin, 30 October 2018.  The countries in Northern Europe have […]

– An idea needs to attract investors

Meet Thomas Andersson, our new Senior Advisor Business Development. How could he be of help to your startup company?  — The most important thing I do is to get the startup companies rolling. Thomas Andersson, the new Senior Advisor for Business Development at Oslo Cancer Cluster and Oslo Cancer Cluster Incubator, looks dead serious as […]

Prestigious partnership for Vaccibody

Oslo Cancer Cluster member Vaccibody is entering into a clinical collaboration with the American biopharmaceutical company Nektar Therapeutics. The aim of the collaboration is to explore positive effects from the combination of Vaccibody’s personalized cancer vaccine VB10.NEO and Nektar Therapeutics cancer drug NKTR-214. Pre-clinical results of the combination are very positive and the collaboration will […]

American tech and Norwegian health data

Combining country scale population data with world class computer systems and algorithms will push the boundaries of precision medicine. This is a story about the unique American-Norwegian collaboration that combines the best health data with the most powerful computers in a pioneer project run by Cancer Registry of Norway and Lawrence Livermore National Laboratory. Data to screen […]